98 related articles for article (PubMed ID: 35119076)
1. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.
Bao S; Darvishi M; H Amin A; Al-Haideri MT; Patra I; Kashikova K; Ahmad I; Alsaikhan F; Al-Qaim ZH; Al-Gazally ME; Kiasari BA; Tavakoli-Far B; Sidikov AA; Mustafa YF; Akhavan-Sigari R
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7945-7968. PubMed ID: 36905421
[TBL] [Abstract][Full Text] [Related]
2. EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
Sagini MN; Zepp M; Eyol E; Ali DM; Gromova S; Dahlmann M; Behrens D; Groeschel C; Tischmeier L; Hoffmann J; Berger MR; Forssmann WG
Peptides; 2024 May; 175():171111. PubMed ID: 38036098
[TBL] [Abstract][Full Text] [Related]
3. Hormophysa triquerta polyphenol, an elixir that deters CXCR4- and COX2-dependent dissemination destiny of treatment-resistant pancreatic cancer cells.
Aravindan S; Ramraj S; Kandasamy K; Thirugnanasambandan SS; Somasundaram DB; Herman TS; Aravindan N
Oncotarget; 2017 Jan; 8(4):5717-5734. PubMed ID: 27974694
[TBL] [Abstract][Full Text] [Related]
4. Targeting the CXCL12/CXCR4 pathway to reduce radiation treatment side effects.
Chaudary N; Hill RP; Milosevic M
Radiother Oncol; 2024 May; 194():110194. PubMed ID: 38447871
[TBL] [Abstract][Full Text] [Related]
5. SAP deletion promotes malignant insulinoma progression by inducing CXCL12 secretion from CAFs via the CXCR4/p38/ERK signalling pathway.
Jiang G; Xu S; Mai X; Tu J; Wang L; Wang L; Zhan Y; Wang Y; Zhang Q; Zheng L; Li J; Tang P; Qi C
J Cell Mol Med; 2024 May; 28(10):e18397. PubMed ID: 38766687
[TBL] [Abstract][Full Text] [Related]
6. Girdin regulates both migration and angiogenesis in pancreatic cancer cell lines.
Hayashi Y; Matsuo Y; Denda Y; Nonoyama K; Murase H; Ueda G; Aoyama Y; Kato T; Omi K; Imafuji H; Saito K; Morimoto M; Ogawa R; Takahashi H; Mitsui A; Kimura M; Takiguchi S
Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37503752
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of integrin‑linked kinase enhances tumor progression in gemcitabine‑resistant pancreatic cancer.
Murase H; Matsuo Y; Denda Y; Nonoyama K; Kato T; Aoyama Y; Hayashi Y; Imafuji H; Saito K; Morimoto M; Ogawa R; Takahashi H; Mitsui A; Kimura M; Takiguchi S
Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37477162
[TBL] [Abstract][Full Text] [Related]
8. The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets.
Roberto M; Arrivi G; Di Civita MA; Barchiesi G; Pilozzi E; Marchetti P; Santini D; Mazzuca F; Tomao S
Front Oncol; 2023; 13():1154581. PubMed ID: 37035150
[TBL] [Abstract][Full Text] [Related]
9. SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival.
Wang RX; Ji P; Gong Y; Shao ZM; Chen S
Front Immunol; 2022; 13():940635. PubMed ID: 36341391
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase receptor RON activates MAPK/RSK/CREB signal pathway to enhance CXCR4 expression and promote cell migration and invasion in bladder cancer.
Chen J; Wang K; Ye S; Meng X; Jia X; Huang Y; Ma Q
Aging (Albany NY); 2022 Sep; 14(17):7093-7108. PubMed ID: 36103228
[TBL] [Abstract][Full Text] [Related]
11. Regulation of pancreatic cancer therapy resistance by chemokines.
Gautam SK; Basu S; Aithal A; Dwivedi NV; Gulati M; Jain M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):69-80. PubMed ID: 36064086
[TBL] [Abstract][Full Text] [Related]
12. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer.
Matsuo Y; Ochi N; Sawai H; Yasuda A; Takahashi H; Funahashi H; Takeyama H; Tong Z; Guha S
Int J Cancer; 2009 Feb; 124(4):853-61. PubMed ID: 19035451
[TBL] [Abstract][Full Text] [Related]
13. CXCL12-CXCR4 promotes proliferation and invasion of pancreatic cancer cells.
Shen B; Zheng MQ; Lu JW; Jiang Q; Wang TH; Huang XE
Asian Pac J Cancer Prev; 2013; 14(9):5403-8. PubMed ID: 24175834
[TBL] [Abstract][Full Text] [Related]
14. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
[TBL] [Abstract][Full Text] [Related]
15. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
16. Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer.
Kato T; Matsuo Y; Ueda G; Murase H; Aoyama Y; Omi K; Hayashi Y; Imafuji H; Saito K; Morimoto M; Ogawa R; Takahashi H; Takiguchi S
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35119076
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
